Peptide receptor radionuclide therapy (PRRT) special issue

Shaunak Navalkissoor¹, Robert P Millar^{2

3}

Affiliations

¹ Department of Nuclear Medicine and Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation Trust, London, UK.
² Centre for Neuroendocrinology, University of Pretoria, Pretoria, South Africa.
³ Department of Integrative Biomedical Sciences, Faculty of Health Sciences, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Editorial

Shaunak Navalkissoor et al. J Neuroendocrinol. 2025 Mar.

. 2025 Mar;37(3):e70014.

doi: 10.1111/jne.70014. Epub 2025 Mar 2.

Shaunak Navalkissoor¹, Robert P Millar^{2

3}

¹ Department of Nuclear Medicine and Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation Trust, London, UK.
² Centre for Neuroendocrinology, University of Pretoria, Pretoria, South Africa.
³ Department of Integrative Biomedical Sciences, Faculty of Health Sciences, Institute for Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

No abstract available

References

1. Levine R, Krenning EP. Clinical history of the Theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of Eric P. Krenning by Rachel Levine. J Nucl Med. 2017;58(Suppl 2):3S‐9S.
1. Hennrich U, Kopka K. Lutathera(®): the first FDA‐and EMA‐approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals Basel. 2019;12(3):114.
1. https://pubmed.ncbi.nlm.nih.gov/?term=prrt&filter=dates.2020%2F1%2F1... Search Term “PRRT” 16.01.2025.
1. Kuiper J, Zoetelief E, Brabander T, de Herder WW, Hofland J. Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours. J Neuroendocrinol. 2025;37(3):e13469. doi:10.1111/jne.13469
1. Parghane RV, Basu S. Toxicity manifestations encountered in peptide receptor radionuclide therapy setting. J Neuroendocrinol. 2025;37(3):e13464. doi:10.1111/jne.13464